Hong Kong Metals and Mining Stock News

HSBC’s upgrade of Nongfu Spring (SEHK:9633) from Hold to Buy has put fresh attention on the stock, with the bank highlighting new sugar ready to drink teas and Tan Bing branded coffees as growth drivers. See our latest analysis for Nongfu Spring. The upgrade lands after a choppy stretch, with a 30 day share price return of minus 6.8 percent and a 90 day share price return of minus 12.7 percent. However, a strong year to date share price return of 43.3 percent and a 1 year total shareholder...

Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the story behind the stock. See our latest analysis for Ascentage Pharma Group International. The latest ASH data land after a bumpy stretch, with a 30 day share price return of minus 11.8 percent and a 90 day share price return of minus 25.1 percent. However, a much stronger year to date share price...

Tingyi (Cayman Islands) Holding (SEHK:322) has kicked off a major leadership transition, with long serving CEO Chen Yinjang set to retire at the end of 2025 and Wei Hong Chen stepping in from January 2026. See our latest analysis for Tingyi (Cayman Islands) Holding. The leadership handover comes as Tingyi’s 90 day share price return of 11.55 percent and year to date share price return of 21.22 percent signal improving momentum. A 1 year total shareholder return of 29.75 percent shows the...

Aluminum Corporation of China (SEHK:2600) just shook things up with a completed capital contribution to Yunnan Aluminum Foil, backing a new energy high precision sheet, strip, and foil project that sharpens its high end growth trajectory. See our latest analysis for Aluminum Corporation of China. The move into high precision new energy materials comes after a strong run, with Aluminum Corporation of China’s share price returning around 51% over 90 days and a 1 year total shareholder return...

Earlier this month, InnoCare Pharma received CDE approval in China to begin a Phase II/III trial of its novel TYK2 inhibitor soficitinib for chronic spontaneous urticaria, expanding its autoimmune and dermatology pipeline. This move deepens InnoCare’s push beyond oncology into chronic inflammatory skin diseases, targeting a large, under-served CSU patient population in China that requires long-term treatment. We’ll now examine how advancing soficitinib into Phase II/III for chronic...

Earlier this week, China’s Ministry of Commerce announced it would review and supervise CK Hutchison Holdings’ overseas port asset sales to ensure fair competition and protect national sovereignty, security, and development interests. This added layer of Chinese regulatory oversight introduces fresh uncertainty around the timing and structure of CK Hutchison’s port divestments, potentially affecting how investors assess its portfolio reshaping efforts. Next, we’ll examine how this new...

Earlier this week, Zhongsheng Group Holdings announced that long-serving independent non-executive director and audit committee chair Mr. Ying Wei resigned on 19 December 2025, with tax specialist Mr. Bai Fengjiu appointed to both roles the same day. Alongside these board changes, the company published detailed board and committee compositions, giving investors clearer visibility into its governance and oversight structure. We’ll now examine how the refreshed audit committee leadership and...

China Shenhua Energy (SEHK:1088) just released its November and year to date operating update, with softer coal volumes but stronger polyethylene and polypropylene sales, giving investors a mixed read on the company’s core and chemical businesses. See our latest analysis for China Shenhua Energy. The stock has been resilient despite softer coal numbers. The latest HK$39.68 close underpins a 21.9% year to date share price return and a standout 36.9% one year total shareholder return,...

MGM China Holdings has appointed long-serving executive Kenneth Xiaofeng Feng as chief executive officer, effective December 19, 2025, after more than two decades in varied finance, operations and development roles across the MGM group. By elevating its president and executive director, with deep international operations and audit committee experience, to a three-year CEO term, the board is signaling confidence in continuity and execution-focused leadership for its Macau business. We’ll now...

China Hongqiao Group Added to a Key Benchmark China Hongqiao Group (SEHK:1378) just joined the Hang Seng China Enterprises Index. This shift can pull in institutional money and passive index tracking capital, subtly reshaping the stock’s demand dynamics. See our latest analysis for China Hongqiao Group. The inclusion comes after a powerful run, with the latest share price at HK$31.7 and a year to date share price return of 178.56%, backed by a 1 year total shareholder return of 193.30% that...

Tencent Holdings (SEHK:700) is back in focus after China’s video game industry hit a new revenue high, while the company quietly tapped Japanese cloud partners to access Nvidia Blackwell chips despite ongoing US export controls. See our latest analysis for Tencent Holdings. Those themes are already feeding into sentiment, with the share price up strongly on a year to date basis and a solid one year total shareholder return suggesting momentum is still broadly constructive rather than...

Earlier in December 2025, SSY Group announced that it had received NMPA approval in China to produce and register Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules, both classified as having passed consistency evaluation. These approvals deepen SSY Group’s ophthalmic and gastrointestinal product lineup, potentially strengthening its position in specialist hospital and pre-procedure medication markets. We’ll now examine how the NMPA approvals, particularly the Levofloxacin Eye...

Beijing Fourth Paradigm Technology (SEHK:6682) just pushed through a package of governance changes at its December meetings, revising its Articles, refreshing its English name, and adding independent director Pan Jialin to the board. See our latest analysis for Beijing Fourth Paradigm Technology. These governance moves come after a tough stretch, with the latest HK$42.74 quote sitting against a 90 day share price return of minus 34.45% and a 1 year total shareholder return of minus 17.49%...

China Longyuan Power Group Corporation Limited reported that its consolidated power generation for November 2025 rose 14.34% year on year to 6,944,492 MWh, with wind output higher and PV output growing very rapidly, and year-to-date 2025 generation edging 0.41% above the same period in 2024. An interesting takeaway is that, excluding coal power, the company’s 2025 output increased 12.07% year on year, driven by a 72.42% surge in PV generation and solid growth in wind. We will now look at how...

Cathay Pacific Airways (SEHK:293) has quietly rewarded patient investors, with the share price climbing around 37% over the past year and nearly doubling over five years as travel demand normalizes. See our latest analysis for Cathay Pacific Airways. That momentum is still very much alive, with a 90 day share price return of about 13.5% and a 1 year total shareholder return above 37%. This suggests confidence in the airline recovery story is building rather than fading. If Cathay’s rebound...

Key Insights Significant control over Abbisko Cayman by retail investors implies that the general public has more power...

Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors. See our latest analysis for Shanghai Henlius Biotech. That HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...

CStone Pharmaceuticals announced on 8 December 2025 that its targeted therapy GAVRETO (pralsetinib, 100 mg) has been included in China’s latest National Reimbursement Drug List, which will take effect on 1 January 2026 and broaden reimbursed access for RET-altered lung and thyroid cancer patients. The NRDL inclusion, combined with CStone’s existing commercialization partnership with Shanghai Allist in Mainland China, underscores how alliance-driven distribution is central to expanding...

Yadong Group Holdings Limited ( HKG:1795 ) shares have had a horrible month, losing 29% after a relatively good period...

Forward Fashion (International) Holdings Company Limited ( HKG:2528 ) shareholders have had their patience rewarded...

The Hing Ming Holdings Limited ( HKG:8425 ) share price has softened a substantial 28% over the previous 30 days...

The Seven Elements Investment Holdings Limited ( HKG:1660 ) share price has softened a substantial 27% over the...

Zhejiang Shibao Company Limited ( HKG:1057 ) shareholders would be excited to see that the share price has had a great...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...